Intellia Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Name: Intellia Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Intellia Therapeutics Inc
Rating: 1.32266675
Author: Trendlyne DVM scores

Momentum Trap

about

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a rev...

11.54 -0.41 (-3.43%)

59.05% Fall from 52W High

1.4M

XNAS Volume

XNAS 15 Jul, 2025 11:24 AM (EDT)

Low Financial Strength

16.7 / 100

Expensive Valuation

14.5 / 100

Technically Neutral

58.0 / 100

Momentum Trap These stocks are the ones with poor quality and also financials and technical ranging from bad to medium score. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM

1Yr Price target upside is 222%

27 analysts

Intellia Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Intellia Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a rev...

59.05% Fall from 52W High

SWOT Analysis

Intellia Therapeutics Inc Live Price Chart